| Epidemiology domain | Statistic / finding | Value | Population / scope | Year / source framing | Citation |
|---|---|---:|---|---|---|
| Global incidence | New bladder cancer cases worldwide | 573,000 | Global, all bladder cancers; >90% are urothelial / transitional-cell histology | GLOBOCAN 2020 summarized in 2023 review | (pqac-00000008, pqac-00000001) |
| Global incidence | New bladder cancer cases worldwide | 613,799 | Global, all bladder cancers | GLOBOCAN 2022 summarized in 2024 review | (pqac-00000000) |
| Global incidence | Bladder cancer rank among all cancers | 10th most common cancer globally | Global | 2020 review synthesis | (pqac-00000008) |
| Global incidence | Age-standardized incidence rate (ASR) | 5.6 per 100,000 | Global | 2022 global estimate | (pqac-00000000) |
| Global incidence by sex | Male incident cases | 471,077 (76.7%) | Global | 2022 global estimate | (pqac-00000000) |
| Global incidence by sex | Female incident cases | 142,722 (23.3%) | Global | 2022 global estimate | (pqac-00000000) |
| Sex ratio | Male:female incident case ratio | ~3.3:1 | Global, based on 471,077 vs 142,722 cases | 2022 global estimate | (pqac-00000000) |
| Global mortality | Bladder cancer deaths worldwide | 220,347 | Global | 2022 global estimate | (pqac-00000000) |
| Global mortality | Age-standardized mortality rate | 1.9 per 100,000 | Global | 2022 global estimate | (pqac-00000000) |
| Global mortality by sex | Male share of bladder cancer deaths | 75.1% | Global | 2022 global estimate | (pqac-00000000) |
| Global prevalence | 5-year prevalence | 490,902 | Global | 2022 global estimate | (pqac-00000000) |
| Prevalence distribution | Highest regional share of 5-year prevalence | Europe 154.4 | Regional share as reported in review | 2022 global estimate summarized in 2024 review | (pqac-00000000) |
| Prevalence distribution | Other regional 5-year prevalence shares | Asia 131.1; North America 66.8; Latin America/Caribbean 21.5; Africa 19.6; Oceania 3.6 | Regional shares as reported in review | 2022 global estimate summarized in 2024 review | (pqac-00000000) |
| Geographic distribution | Highest male ASR reported | 40 per 100,000 | Greece | GLOBOCAN 2020 summarized in 2023 review | (pqac-00000008) |
| Geographic distribution | Lowest male ASR reported | <1 per 100,000 | Several African countries, including Côte d’Ivoire and Liberia | GLOBOCAN 2020 summarized in 2023 review | (pqac-00000008) |
| Geographic distribution | Highest female ASR reported | 9 per 100,000 | Hungary | GLOBOCAN 2020 summarized in 2023 review | (pqac-00000008) |
| Geographic distribution | Lowest female ASR reported | <1 per 100,000 | Several African and Eastern Mediterranean countries | GLOBOCAN 2020 summarized in 2023 review | (pqac-00000008) |
| Age distribution | Median age at diagnosis | 70 years | Bladder cancer overall | 2024 review | (pqac-00000000) |
| Age distribution (advanced disease cohort) | Median age at start of first-line treatment | 73 years (IQR 66–80) | US advanced urothelial carcinoma cohort, n=7,260 | 2011–2023 EHR cohort, published 2024 | (pqac-00000006) |
| US burden | Projected new bladder cancer cases | 82,290 | United States | 2023 projection, reported in 2024 study | (pqac-00000006) |
| US burden | Projected bladder cancer deaths | 16,710 | United States | 2023 projection, reported in 2024 study | (pqac-00000006) |
| Stage distribution at presentation | Non-muscle-invasive bladder cancer (NMIBC) at diagnosis | ~70–75% | Bladder urothelial carcinoma | 2023–2024 reviews | (pqac-00000003, pqac-00000012) |
| Stage distribution at presentation | Muscle-invasive bladder cancer (MIBC) at diagnosis | ~25–30% | Bladder urothelial carcinoma | 2023–2024 reviews | (pqac-00000001, pqac-00000003, pqac-00000011, pqac-00000012) |
| Histology distribution | Urothelial / transitional cell carcinoma among bladder cancers | 90–95% | Bladder cancer overall | 2023–2024 reviews | (pqac-00000001, pqac-00000002, pqac-00000004, pqac-00000011) |
| Upper tract share | Upper tract urothelial carcinoma (UTUC) among urothelial carcinomas | 5–10% | Urothelial carcinoma overall | 2023–2024 reviews | (pqac-00000002, pqac-00000005) |
| UTUC stage distribution | Invasive disease at diagnosis | ~60% | Upper tract urothelial carcinoma | 2023 review | (pqac-00000002) |
| UTUC stage distribution | Metastatic disease at diagnosis | ~30% | Upper tract urothelial carcinoma | 2023 review | (pqac-00000002) |
| Clinical presentation | Hematuria frequency in UTUC | ~80% | Upper tract urothelial carcinoma | 2024 guideline review | (pqac-00000005) |
| Temporal trend | Expected global case trend | Number of new cases expected to double by 2040 | Global bladder cancer burden | WHO-based projection summarized in 2023 review | (pqac-00000001) |
| Temporal trend | Incidence pattern | Incidence has not been stable worldwide over time and is influenced by ageing, population growth, and smoking exposure | Global | 2023 epidemiology review | (pqac-00000008) |
| Survival context | 5-year survival for localized bladder cancer | 71% | United States | Reported in 2024 cohort study | (pqac-00000006) |
| Survival context | 5-year survival for metastatic bladder cancer | 8.3% | United States | Reported in 2024 cohort study | (pqac-00000006) |
| Survival context | NMIBC overall survival | 90% | General bladder cancer review context | 2024 BMJ review | (pqac-00000012) |


*Table: This table compiles recent 2023-2024 epidemiology statistics for transitional cell carcinoma/urothelial carcinoma, including incidence, mortality, prevalence, demographics, geography, stage at presentation, and time trends. It is useful as a quick-reference summary for disease burden and population characteristics.*